Epizyme logo
Epizyme EPZM
report update icon

Quarterly report 2022-Q2
added 05-23-2026

Epizyme Gross Profit | EPZM

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Epizyme

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
- 10.7 M - - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
10.7 M 10.7 M 10.7 M

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
AbbVie AbbVie
ABBV
12.1 B $ 263.04 0.49 % $ 465 B usaUSA
Фармсинтез Фармсинтез
LIFE
160 M - - - russiaRussia
Aclaris Therapeutics Aclaris Therapeutics
ACRS
172 K $ 5.53 6.02 % $ 678 M usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
116 M - - $ 621 M britainBritain
Clovis Oncology Clovis Oncology
CLVS
123 M - -7.23 % $ 13 M usaUSA
Chimerix Chimerix
CMRX
212 K - - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
7.9 K - - $ 401 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
293 M $ 8.61 0.16 % $ 2.05 B usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
5.39 M - -0.31 % $ 3.64 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
1.36 K - -15.0 % $ 3.04 M usaUSA
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
248 M - - $ 643 M usaUSA
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
91.4 K - - $ 13.6 B usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
17.3 M - - $ 2.6 B usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
975 K - -3.69 % $ 12.4 M usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
25.6 M - - $ 154 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
3.45 M - - $ 229 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
936 K - - $ 35.3 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
137 M - - $ 216 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
3.03 M - - $ 3.3 B usaUSA
9 Meters Biopharma 9 Meters Biopharma
NMTR
-64 K - -42.97 % $ 1.05 M usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
1 K - -19.68 % $ 18.4 M canadaCanada
Oncternal Therapeutics Oncternal Therapeutics
ONCT
3.38 M - -24.12 % $ 1.56 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
23.4 M - - $ 109 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
1.74 M - 1.02 % $ 90.8 M britainBritain